Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
15 Mar 2022 |
On significant placements in financial instruments |
Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A.
|
Download |
|
14 Mar 2022 |
On significant placements in financial instruments |
Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A.
|
Download |
|
23 Feb 2022 |
On business and financial situation |
The Company releases the press release related to the full year 2021 financial results
|
Download |
|
23 Feb 2022 |
On business and financial situation |
The Company releases the full year 2021 financial results presentation
|
Download |
|
23 Feb 2022 |
About corporate governance |
The Company informs about the agreements adopted by the Board of Directors
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
27 Jul 2022 |
On business and financial situation |
The Company releases the press release related to the first half 2022 financial results
|
Download |
|
27 Jul 2022 |
On business and financial situation |
The Company releases the first half 2022 financial results presentation
|
Download |
|
04 Jul 2022 |
Liquidity and counterparty agreements |
Liquidity contract: transactions conducted in the second quarter of 2022
|
Download |
|
30 Jun 2022 |
Other relevant information |
The Company informs about the dividends payment
|
Download |
|
16 Jun 2022 |
Other relevant information |
The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
04 Apr 2019 |
Liquidity contracts and specialists |
Liquidity contract: transactions conducted in the first quarter of 2019
|
Download |
|
19 Mar 2019 |
R&D: new licenses, patents and registered trademarks |
ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia
|
Download |
|
26 Feb 2019 |
Informe Anual de Remuneraciones de los Consejeros |
ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors
|
Download |
|
26 Feb 2019 |
Informe Anual de Gobierno Corporativo |
ROVI releases the 2018 Annual Corporate Governance Report
|
Download |
|
26 Feb 2019 |
Otros sobre gobierno corporativo |
The Company informs about the agreements adopted by the Board of Directors
|
Download |
Pages
